No Data
TOT BIOPHARM-B: INTERIM REPORT 2024
Dongyao Pharmaceuticals (1875.HK): CDMO project pool expands steadily, combining certainty and growth.
On August 7th, Hang Seng Index Company stated in an article that the biotech sector has shown signs of improvement recently, benefiting from policy support and a continuous inflow of funds over the past three months. With more policies being implemented, the Hang Seng Hong Kong-listed Biotech Index has outperformed the market since July. Clearly, the positive changes revealed in Hang Seng's article provide investors with a new perspective, which may also indicate a new turning point for the entire healthcare sector. In the current situation where the entire sector is still undervalued, as pharmaceutical companies enter the earnings season in the near future, it also brings a window of opportunity for the market to assess company value and predict future development. Recently, the interim report of the company was released.
TOT Biopharm International Turns to Profit in H1
Dongyang Pharmaceutical Company-B announced its mid-year performance. The net income for the first half of the year was RMB 31.559 million, a turned profit from a loss compared to the same period last year.
Dongyao Pharmaceutical-B (01875) released its six-month performance until June 30, 2024. The group obtained revenue of RMB 0.521 billion (unit in the following), a year-on-year increase of 58.69%. The company's equity holders' profit was RMB 31.559 million, compared with a loss of RMB 15.163 million in the same period last year, with a profit per share of RMB 0.04. Sales revenue of the product during the period was RMB 0.4004 billion, a year-on-year increase of 44%, mainly from the core product Bevacizumab Injection Poxin (PD-L1) with continued growth in sales. The income of CDMO/CMO business reached RMB 0.114 billion, a year-on-year increase of 144%, and the hematopoietic capacity was stable.
Dongyao Pharmaceutical-B (01875.HK) achieved a net profit of 31.559 million yuan in the first half of the year, reversing its previous loss.
On August 13, Gelonhui announced that the business revenue of Dongyao Pharmacy-B (01875.HK) was RMB 0.52 billion in the first half of 2024, an increase of 59% year-on-year. Among them, product sales revenue was RMB 0.4 billion, a year-on-year increase of 44%, mainly from the core product Bevacizumab injection sales of Poxinting. The revenue of CDMO/CMO business reached RMB 0.114 billion, an increase of 144% year-on-year. Hematopoietic ability is stable, and the net cash flow from operating activities in the first half of the year was RMB 27,801 thousand, which has continued to be positive. The strategic transformation of CDMO has achieved significant results and sales of self-developed products have also remained stable.
Express News | TOT BIOPHARM International H1 Cash Flow From Operating Activities RMB 27.801 Million
No Data
No Data